1Lane HA, Breulex M. Optimal targeting of the mTORC1 kinase in human cancer [J]. Curr Opin Cell Biol , 2009,21 (2) : 219-29.
2Baldo P,Cecco S,Giacomin E,et a1. mTOR pathway andmTOR inhibitors as agents for cancer therapy[J]. Curr Cancer Drug Targets, 2008,8(8) : 647-65.
3Wanner K, Hipp S,Oelsner K ,et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab[J]. Br ] Haematol,2006,134(5) :475-84.
4Gupta MvAnsell SM,Novak AJ ,et a1. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 [J]. Blood, 2009, 114( 14) : 2926-35.
6Smith SM,van Besien Kv Karrison Tv et al. Temsirolimus has activity in non-mantle cell non-Hodgkins lymphoma subtypes: theuniversity of Chicago phase II consortium[J]. J Clin Oncol , 2010,28(31):4740-6.
7OReilly KE,Rojo F,She QB,et a1. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J]. Cancer Res,2006,66(3): 1500-8.
二级参考文献8
1Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-Bcell lymphoma. N Engl J Med, 2002, 346(25) :1937-1947.
2Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103( 1 ) :275-282.
3Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood, 1998, 92(9) :3152-3162.
4Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary cenlral nervous system lymphoma: analysis of 83 cases. Blood, 2005, 107( 1 ) : 190-196.
5Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol, 2005, 18(3 ) : 398-405.
6Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large Bcell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol, 2005,23(12) :2797-2804.
7Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 2005, 18(8) :1113-1120.
8Muffs J, Meijer C, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk slratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 2006, 208(5) :714-723.
